Stay updated on Durvalumab After Radiation in Stage 3 NSCLC – Clinical Trial
Sign up to get notified when there's something new on the Durvalumab After Radiation in Stage 3 NSCLC – Clinical Trial page.

Latest updates to the Durvalumab After Radiation in Stage 3 NSCLC – Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange Detected- Added a government operations notice and operating details, plus a new v3.2.0 revision. - Removed the previous v3.1.0 revision.SummaryDifference10% 
- Check34 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0. The core page content shifts to the newer release identifier; no other substantive content changes are indicated.SummaryDifference0.2% 
- Check48 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2, and the 'Back to Top' element was removed.SummaryDifference0.6% 
- Check55 days agoChange DetectedThe web page has been updated from version 3.0.0 to 3.0.1, indicating a revision in the content. There are no significant changes to core content or important information.SummaryDifference0.6% 
- Check62 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location details, while removing specific location terms and listed countries. These changes enhance the clarity and relevance of the page's content.SummaryDifference35% 
- Check77 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.3% 
Stay in the know with updates to Durvalumab After Radiation in Stage 3 NSCLC – Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab After Radiation in Stage 3 NSCLC – Clinical Trial page.